The biggest biopharmaceutical company in the state is getting bigger. Rensselaer County legislators gave their approval Tuesday night. Our Erin Vannella has the details.
EAST GREENBUSH, N.Y. -- "We have three FDA approved drugs that are now on the market and all of those drug products are manufactured right there in Rensselaer County, New York, in East Greenbush," said Regeneron Pharmaceutical spokesperson Peter Dworkin.
Regeneron Pharmaceuticals is growing its Capital Region stronghold by $70 million, 65,000 square feet and 300 new jobs.
"We'll be hiring engineers, IT specialists, production workers, quality control specialists among others, providing well paid jobs for highly skilled workers," said Dworkin.
It's more good news on the tech front, a booming industry here and abroad, that draws from an increasingly local talent base. It's one the governor and local legislators are proud to support.
"It's just another avenue to provide great jobs for our young people and to keep them here in this community," said Rensselaer County Executive Kathy Jimino.
The project will require building two new sites over the next three years. Yes, that means about 100 construction jobs, too. And it's not an investment Regeneron considers risky. They've been in the Capital Region since 1988, growing steadily since, and the local economy with it.
"It sends a message that Rensselaer County and New York State are a great place to do business and hopefully as we look to do business and competing on a global basis this will give us a bit of a leg up," said Jimino.
It looks like the Capital Region could be gaining a few new jobs after news that Regeneron Pharmaceuticals is investing $70 million to expand its production facility. Peter Dworgin from Regeneron joined us on the phone with more on the expansion.
YNN: Regeneron Pharmaceuticals expanding
Time Warner Cable video customers:
Sign in with your TWC ID to access our video clips.
To view our videos, you need to
install Adobe Flash 9 or above. Install now.
Then come back here and refresh the page.